The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers.
advanced-stage diabetic kidney disease
renin-angiotensin system blocker
sodium-glucose cotransporter-2 inhibitor
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
08
2019
accepted:
20
01
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
27
2
2020
Statut:
epublish
Résumé
We investigated the efficacy and safety of sodium-glucose cotransporter-2 (SGLT-2) inhibitors as an add-on therapy in patients with advanced-stage diabetic kidney disease taking renin-angiotensin system (RAS) blockers. Changes in glycated hemoglobin (HbA1c), urine protein-to-creatinine ratio (UACR), body weight, systolic blood pressure, and annual change in estimated glomerular filtration rate (eGFR) were retrospectively analyzed in 20 patients after 12 months of SGLT-2 inhibitor administration (mean eGFR: 22.8 ± 9.7 mL/min/1.73 m The annual change in eGFR improved significantly from -8.6 ± 12.5 mL/min/1.73 m Using SGLT-2 inhibitors as an add-on therapy may have beneficial effects on renal function in patients with advanced-stage diabetic kidney disease taking RAS blockers without any adverse effects.
Identifiants
pubmed: 32099428
doi: 10.2147/DMSO.S229046
pii: 229046
pmc: PMC7005728
doi:
Types de publication
Journal Article
Langues
eng
Pagination
215-225Informations de copyright
© 2020 Hirai et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Biol Chem. 2017 Mar 31;292(13):5335-5348
pubmed: 28196866
Lancet. 2015 May 23;385(9982):2047-56
pubmed: 26009228
Clin Kidney J. 2018 Dec;11(6):749-761
pubmed: 30524708
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Endocrinol Diabetes Metab. 2018 Mar 26;1(2):e00015
pubmed: 30815551
BMJ. 2004 Oct 9;329(7470):828
pubmed: 15459003
J Renal Inj Prev. 2015 Jun 01;4(2):28-33
pubmed: 26060834
Circulation. 2014 Feb 4;129(5):587-97
pubmed: 24334175
Physiol Rep. 2015 Jul;3(7):
pubmed: 26169541
Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621
pubmed: 28666775
Diabetes. 2013 Oct;62(10):3324-8
pubmed: 24065789
Kidney Int. 2018 Jan;93(1):231-244
pubmed: 28860019
Circ J. 2016 Oct 25;80(11):2277-2281
pubmed: 27599528
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Diabetes Obes Metab. 2016 Aug;18(8):783-94
pubmed: 27059700
Drug Saf. 2018 Mar;41(3):239-252
pubmed: 28952138
Arch Pharm Res. 2014 Aug;37(8):957-66
pubmed: 24950857
Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F227-34
pubmed: 26041448